Fosamax Duration of Use Questioned by FDA

In September, The FDA’s Reproductive Health Drugs Advisory Committee and the Drug safety and Risk Management Advisory Committee held a joint meeting to discuss the appropriate duration of use for Fosamax and other bisphosphonates. Earlier this year the FDA required manufacturers to include language in their labels stating that the optimal duration for patient use…